The latest price target for Leap Therapeutics (NASDAQ:LPTX) was reported by HC Wainwright & Co. on January 29, 2025. The analyst firm set a price target for $0.00 expecting LPTX to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Leap Therapeutics (NASDAQ:LPTX) was provided by HC Wainwright & Co., and Leap Therapeutics downgraded their neutral rating.

There is no last upgrade for Leap Therapeutics

The last downgrade for Leap Therapeutics Inc happened on January 29, 2025 when HC Wainwright & Co. changed their price target from N/A to N/A for Leap Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Leap Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Leap Therapeutics was filed on January 29, 2025 so you should expect the next rating to be made available sometime around January 29, 2026.

While ratings are subjective and will change, the latest Leap Therapeutics (LPTX) rating was a downgraded with a price target of $0.00 to $0.00. The current price Leap Therapeutics (LPTX) is trading at is $0.48, which is out of the analyst’s predicted range.